FILE - In this Thursday, Feb. 9, 2012 file photo, a pharmacist works in a lab where medicines are being produced at a Cipla manufacturing unit on the outskirts of Mumbai, India. A lawyer for ... more 
FILE - In this Thursday, Feb. 9, 2012 file photo, a pharmacist works in a lab where medicines are being produced at a Cipla manufacturing unit on the outskirts of Mumbai, India. A lawyer for healthcare activists says India's Supreme Court has rejected drug maker Novartis AG' right to patent a new version of a lifesaving cancer drug. The landmark ruling today is a victory for India's (Canadian) $26 billion generic drug industry that provides cheap medicines to millions around the world. Novartis has fought a legal battle in India since 2006 for a fresh patent for its cancer drug Glivec. Cipla makes a generic version of Glivec. (AP Photo/Rafiq Maqbool, File) less 
1 / 30
Associated Press | Photo By Rafiq Maqbool, File
Mon, Apr 1, 2013 4:20 AM EDT